430 related articles for article (PubMed ID: 16288119)
1. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
2. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
3. Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope.
Navari M; Zare M; Javanmardi M; Asadi-Ghalehni M; Modjtahedi H; Rasaee MJ
Immunopharmacol Immunotoxicol; 2014 Oct; 36(5):309-15. PubMed ID: 25070131
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
5. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab.
Wang A; Cui M; Qu H; Di J; Wang Z; Xing J; Wu F; Wu W; Wang X; Shen L; Jiang B; Su X
Oncotarget; 2016 Nov; 7(46):75293-75306. PubMed ID: 27659529
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
[TBL] [Abstract][Full Text] [Related]
7. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
Riemer AB; Hantusch B; Sponer B; Kraml G; Hafner C; Zielinski CC; Scheiner O; Pehamberger H; Jensen-Jarolim E
Cancer Immunol Immunother; 2005 Jul; 54(7):677-84. PubMed ID: 15565329
[TBL] [Abstract][Full Text] [Related]
8. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice.
Brämswig KH; Knittelfelder R; Gruber S; Untersmayr E; Riemer AB; Szalai K; Horvat R; Kammerer R; Zimmermann W; Zielinski CC; Scheiner O; Jensen-Jarolim E
Clin Cancer Res; 2007 Nov; 13(21):6501-8. PubMed ID: 17975163
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
11. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
12. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
13. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study.
Asadi-Ghalehni M; Ghaemmaghami M; Klimka A; Javanmardi M; Navari M; Rasaee MJ
Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):274-9. PubMed ID: 25990849
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
Kimura H; Sakai K; Arao T; Shimoyama T; Tamura T; Nishio K
Cancer Sci; 2007 Aug; 98(8):1275-80. PubMed ID: 17498200
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
[TBL] [Abstract][Full Text] [Related]
18. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination.
Riemer AB; Untersmayr E; Knittelfelder R; Duschl A; Pehamberger H; Zielinski CC; Scheiner O; Jensen-Jarolim E
Cancer Res; 2007 Apr; 67(7):3406-11. PubMed ID: 17409451
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
[TBL] [Abstract][Full Text] [Related]
20. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
